Co-led Elion Therapeutics' $81 million Series B funding round alongside Deerfield Management.
Elion Therapeutics is a biotechnology company focused on combating life-threatening invasive fungal infections
Elion Therapeutics is a biotechnology company focused on combating life-threatening invasive fungal infections. The company aims to provide new therapies that address critical unmet needs in antifungal efficacy and safety.